Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Monoclonal Gammopathy of Undetermined Significance (MGUS): early-phase trial registry
3 of 3 indexed Monoclonal Gammopathy of Undetermined Significance (MGUS) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Monoclonal Gammopathy of Undetermined Significance (MGUS): 3 US clinical trials tracked, 3 recruiting.
Monoclonal Gammopathy of Undetermined Significance (MGUS) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition monoclonal-gammopathy-of-undetermined-significance-mgus
OPEN 3 | RECR 100% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Monoclonal Gammopathy of Undetermined Significance (MGUS) lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Monoclonal Gammopathy of Undetermined Significance (MGUS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Monoclonal Gammopathy of Undetermined Significance (MGUS) is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
NCT02269592
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Wake Forest University Health Sciences
NCT06644625
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Regeneron Pharmaceuticals
NCT06140524
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Monoclonal Gammopathy of Undetermined Significance (MGUS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Monoclonal Gammopathy of Undetermined Significance (MGUS) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Monoclonal Gammopathy of Undetermined Significance (MGUS) page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Monoclonal Gammopathy of Undetermined Significance (MGUS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Monoclonal Gammopathy of Undetermined Significance (MGUS) trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Monoclonal Gammopathy of Undetermined Significance (MGUS) condition card totals 3 registered trials; most-linked intervention Linvoseltamab; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.